The two major fates of fatty acids are mitochondrial oxidation to provide energy for the myocyte and storage within a variety of lipids, where they are stored primarily in discrete lipid droplets or serve as important structural components of membranes. In this review, we provide a brief overview of skeletal muscle fatty acid metabolism and highlight recent notable advances in the field. We then 1) discuss how lipids are stored in and mobilized from various subcellular locations to provide adaptive or maladaptive signals in the myocyte and 2) outline how lipid metabolites or metabolic byproducts derived from the actions of triacylglycerol metabolism or ␤-oxidation act as positive and negative regulators of insulin action. We have placed an emphasis on recent developments in the lipid biology field with respect to understanding skeletal muscle physiology and discuss unanswered questions and technical limitations for assessing lipid signaling in skeletal muscle.
The two major fates of fatty acids are mitochondrial oxidation to provide energy for the myocyte and storage within a variety of lipids, where they are stored primarily in discrete lipid droplets or serve as important structural components of membranes. In this review, we provide a brief overview of skeletal muscle fatty acid metabolism and highlight recent notable advances in the field. We then 1) discuss how lipids are stored in and mobilized from various subcellular locations to provide adaptive or maladaptive signals in the myocyte and 2) outline how lipid metabolites or metabolic byproducts derived from the actions of triacylglycerol metabolism or ␤-oxidation act as positive and negative regulators of insulin action. We have placed an emphasis on recent developments in the lipid biology field with respect to understanding skeletal muscle physiology and discuss unanswered questions and technical limitations for assessing lipid signaling in skeletal muscle.
MUCH HAS BEEN WRITTEN about the increasing obesity epidemic (52) and the associated pathophysiological complications, including insulin resistance and dyslipidemia, which are major factors in the development of type 2 diabetes, cardiovascular disease, and the metabolic syndrome. Obesity is loosely defined as excessive fat accumulation that may impair health, and adipose tissue, by virtue of its large fat mass, is often seen as the major culprit linking obesity to negative health outcomes. However, adipocytes are designed to store vast quantities of fat, and it is other tissues such as the liver, pancreas, and skeletal muscle that are not equipped to store excess fat that become dysfunctional in conditions of "lipid overload" (e.g., high-calorie Western diet, obesity). Indeed, the triacylglycerol (TAG) content of skeletal muscle is usually ϳ0.5% volume density in a lean individual and can increase to only ϳ3.5% in obesity (6) . Although skeletal muscle has a comparatively high capacity for fatty acid oxidation, it is also susceptible to "lipid overload," which can induce insulin resistance and possibly cell death. For these reasons, interventions that increase muscle fatty acid oxidation and/or limit storage have been postulated as therapies for treating obesity-related conditions such as insulin resistance (2, 27, 108, 130, 162) .
Fatty Acid Metabolism in Skeletal Muscle
For the purpose of this review, the term lipid will be defined as fatty acids and their naturally occurring derivatives; hence, a clear understanding of skeletal muscle fatty acid metabolism is required. Additionally, we have summarized literature obtained from studies conducted in immortalized muscle cell lines (C 2 C 12 , L6), primary muscle culture and rodent, and human tissue examined both ex vivo and in vivo. There are limitations to each model, most notably the limited contractile machinery and the low abundance of carnitine in cultured cells, which contributes to reduced rates of fatty acid oxidation. There has been no definitive study to our knowledge directly comparing fatty acid metabolism of each in vivo/ex vivo model under the same experimental conditions. In addition, we present broad concepts based on evidence from studies spanning several species (predominantly human and murine) and highlight to the reader that there are subtle species differences in lipid metabolism that are not discussed.
Long-chain fatty acids are derived primarily from adipocyte lipolysis, where they enter the circulation bound to albumin, and from lipoprotein lipase-mediated breakdown of TAG contained in very low-density lipoproteins and chylomicrons. These fatty acids are taken up into muscle by passive diffusion and by proteinmediated transport, the latter process regulating fatty acid uptake. The major proteins regulating muscle fatty acid transport are fatty acid translocase/cluster of differentiation 36 (FAT/CD36), plasma membrane-associated fatty acid-binding protein (FABPpm) , and a family of fatty acid transport proteins (FATP1 and 4). CD36, FABPpm, FATP1, and FATP4 are coexpressed in skeletal muscle, and all of them contribute to membrane transport, with recent evidence suggesting that CD36 and FATP4 are quantitatively the most important (125) . Once inside the myocyte, fatty acids are reversibly bound to the abundantly expressed cytoplasmic fatty acid-binding protein (FABPc; heart-type isoforms in muscle), which acts as a sink for the incoming fatty acids to protect against the lipotoxic accumulation of free fatty acids and traffics fatty acids throughout cellular compartments. FABPc Ϫ/Ϫ mice have reduced fatty acid oxidation (161) and uptake (107) , suggesting that FABPc is an essential chaperone for efficient fatty acid oxidation and that intracellular fatty acid metabolism plays a significant role in cellular fatty acid uptake. Fatty acids are also derived from de novo lipogenesis in skeletal muscle, but the contribution to the intramyocellular fatty acid pool is small, as is the absolute lipogenic rate when compared with liver and adipose tissue in vivo (1, 93, 171, 200) .
Fatty acids have a multitude of intracellular fates. At the most basic level, the fatty acids can be oxidized or stored. Acyl-CoA synthetases catalyze the coupling of fatty acids with coenzyme A, which is required for ␤-oxidation and the biosynthesis of neutral and membrane lipids. Long-chain acylCoA synthetase isoforms 1, 4, and 6 are expressed in muscle (112) and appear to be key regulators ligating CoA to fatty acyl moieties. Aside from their role in sarcolemmal transport, FATP1 and -4 possess acyl-CoA synthetase activity toward long-and very long-chain fatty acids, and genetic modification studies indicate that both enzymes modulate acyl-CoA synthetase activity in muscle (43, 97) . There is evidence that FATP1 directs fatty acyl-CoA to triglyceride (TAG) synthesis in other cell types (72) and that FATP4 is located at the endoplasmic reticulum, implicating this protein in fatty acid trapping and storage rather than oxidation (43) . Studies in other cell types report that the various acyl-CoA synthase proteins possess distinct enzyme kinetics, differences in their substrate preferences, and localization (111) . Given the importance of these enzymes, it is surprising that their regulatory properties have not been thoroughly investigated in muscle.
Fatty acyl-CoA derived from the plasma and intracellular TAG can be oxidized after mitochondrial transport, which is facilitated by the actions of carnitine palmitoyltransferase I (CPT I). Allosteric regulation of CPT I activity by malonylCoA is well recognized; however, there are several new and exciting mechanisms proposed to regulate fatty acyl-CoA flux through this regulatory checkpoint. A growing body of evidence implicates FAT/CD36 in the regulation of mitochondrial fatty acid oxidation (31, 78) perhaps by localizing to the outer mitochondrial membrane and supplying fatty acid to longchain acyl-CoA synthetase for subsequent import into the matrix by CPT I (163) . Notably, this interpretation is not supported by another study that showed no localization of FAT/CD36 to the mitochondria (89) . FATP1 is also localized to the mitochondria, immunoprecipitates with CPT I, and promotes mitochondrial fatty acid oxidation (105, 154) . Thus, on balance, it appears that CPT I is the critical regulator of mitochondrial fatty acid transport; however, several proteins coassociate to tightly regulate fatty acid delivery, activation, and transport into the mitochondria. The spatial, temporal, and contextual understanding of these associations remains unresolved. Fatty acyl-CoA undergoes ␤-oxidation within the mitochondria, producing substrate for the tricarboxylic acid (TCA) cycle and reducing equivalents for the electron transport chain. Byproducts of fatty acid metabolism are postulated to act as important signals in muscle (see Do byproducts of fatty acid oxidation cause insulin resistance?).
Fatty acids that do not undergo oxidation invariably contribute to lipid synthesis. Studies using radiolabeled palmitate in isolated rodent skeletal muscle indicate that the ratio of exogenous fatty acid storage to oxidation is ϳ2:1, with the vast majority of all fatty acids either oxidized or stored as TAG (90% in soleus) (48) . Although the stored fatty acids are predominantly channeled through the glycerolipid pathway, the absolute flux is influenced by the concentration of the incoming fatty acid, the type of fatty acid (saturated vs. unsaturated), the muscle fiber type (oxidative vs. glycolytic) (48) , the hormonal milieu (49, 132) , and the energy requirements of the muscle (rest vs. contraction) (47) . Evidently, fatty acids are incorporated into other lipid types by the actions of a vast array of enzymes. Analysis of skeletal muscle lipid extracts by mass spectrometry reveals the presence of many lipid species, including glycerolipids, phospholipids, sphingolipids, and cholesterol esters (25). Each of these lipid classes can transduce signals with myocytes, either directly or indirectly, to influence cell function.
Herein, we 1) discuss how lipids are stored and mobilized in various subcellular locations and 2) outline how lipids/lipid metabolites and metabolic byproducts derived from the actions of TAG metabolism or ␤-oxidation act as positive and negative regulators of cell function.
Lipid Droplets in Skeletal Muscle: A Central Point for Lipid Signaling?
Skeletal muscle is an important site for lipoprotein-TAGderived fatty acid (21) and plasma free fatty acid clearance (57) . The major single fate for these fatty acids is TAG esterification, where Յ60% of extracellular-derived fatty acids enter the intracellular TAG pool (21, 47, 147, 148) . This TAG pool serves as an accessible reservoir of highly concentrated energy with an ATP-generating capacity equivalent to muscle glycogen. Together with cholesterol esters and other neutral lipids such as diacylglycerol (DAG), TAGs are stored in discrete organelles termed lipid droplets, which are located near the endoplasmic reticulum (the site of TAG esterification) and the mitochondria (the site of fatty acid oxidation/ATP production) (71, 159, 166) . These lipid droplets are coated in a phospholipid monolayer containing a variety of proteins, including those involved in lipolysis, esterification, motor proteins, and Rab proteins (15, 178, 203) .
Lipase regulation of skeletal muscle lipolysis. The mobilization of stored fatty acids from the TAG pool is catalyzed by three lipases, adipose triglyceride lipase (ATGL), hormonesensitive lipase (HSL), and monoacylglycerol lipase (MAGL), which sequentially degrade TAG, DAG, and monoacylglycerol (MAG), respectively. The processes regulating lipolysis in adipocytes are becoming increasingly complex and are relatively well described (for review, see Refs. 104 and 192) . Herein, we provide some general information regarding the key lipolytic proteins and their role in skeletal muscle lipolysis.
ATGL catalyzes the hydrolysis of TAG to generate DAG and FA (184, 206) and may possess transacylase activity (88) . ATGL lipase activity is enhanced by the interaction with its coactivator comparative gene identification-58 (CGI-58; ABHD5) (103) , whereas lipase activity of ATGL is decreased by G 0 /G 1 switch gene 2, which binds to the patatin-like domain of ATGL (199) . ATGL, CGI-58, and G 0 /G 1 switch gene 2 are expressed in skeletal muscle, and ATGL overexpression in myotubes increased TAG hydrolysis to increase DAG and free fatty acid production (12) . ATGL ablation does not affect contractile function in isolated muscle, suggesting that ATGL may not be an important mediator of TAG hydrolysis during contraction or that TAG is not an important substrate during intense, short-term contractions (83) . The protein-protein interactions and changes in cellular localization of key lipolytic proteins apparent in other cell types have not been examined in muscle. Lipolytic regulation will be different in skeletal muscle given the absence of perilipin 1 (PLIN1), which is an important regulator of lipolysis in adipocytes (see The Role of Lipid Droplet Proteins and Fatty Acid Flux in Skeletal Muscle Function) (120) . ATGL contains several phosphorylation sites, and it appears that the murine Ser 406 residue is phosphorylated by 5=-AMP-activated protein kinase (AMPK) to enhance ATGL activity and lipolysis (5) . The finding of enhanced ATGL activity and lipolysis with AMPK activation contrasts other studies demonstrating decreased HSL activity and lipolysis with AMPK activation (9, 20, 24, 26, 59, 170) . It is presently not clear whether AMPK phosphorylation decreases ATGL-mediated lipolysis in skeletal muscle, nor is it clear why the actions of a regulatory kinase (AMPK) exert opposing actions on two enzymes acting consecutively in the same metabolic pathway.
HSL has broad substrate specificity, including TAG, DAG, MAG, and cholesterol ester lipid classes, and can thereby generate a variety of lipid signals. HSL-null mice have increased muscle DAG content (68) , suggesting that HSL is predominantly a DAG lipase. Studies in ATGL (206) and MAGL-null mice (173) also suggest that HSL plays a minor/ compensatory role as a TAG and MAG lipase. The hydrolase activity of HSL is regulated by reversible phosphorylation at a number of serine sites by PKA, extracellular signal-regulated kinase (ERK), and AMPK. HSL activity in skeletal muscle is increased during exercise due to phosphorylation of the PKA sites (Ser 563 , Ser 659 , and Ser
660
), but AMPK phosphorylation of HSL Ser 565 reduces HSL activity later in prolonged exercise (Ͼ90 min) (142, 143, 191) . HSL translocates to lipid droplets during contraction/␤-adrenergic stimulation in muscle (134) to facilitate increased TAG lipolysis. Thus, phosphorylation of HSL by PKA stimulates lipolysis by increasing lipase activity and moving HSL to its substrates.
The final step in lipolysis is catalyzed by MAGL to convert MAG to glycerol and fatty acid. No study to our knowledge has investigated the regulation of MAGL activity in skeletal muscle.
Lipid droplets and futile cycling. The TAG pool is in a state of constant flux, a process that is alternatively termed the glycerolipid/fatty acid or futile cycle. Contrary to popular claims that the TAG stored in lipid droplets is "inert," the turnover of the TAG pool in resting human skeletal muscle is estimated to be 29 h (146) . When ATP demand from fatty acids is increased by short-term fasting or low-intensity exercise, TAG turnover increases without changes in TAG content, suggesting that lipolysis is matched by synthesis from increased uptake of exogenous fatty acids (67, 146) . TAG content is reduced with higher-intensity exercise due to repartitioning of incoming fatty acids away from esterification and toward oxidation (148) and not intensity-dependent effects on TAG hydrolase activity (189) . It is possible that flux through the TAG pool is critical in regulating myocyte fatty acid traffic, with reports that plasma-derived fatty acids first enter the TAG pool before oxidation and that TAG-derived fatty acids are the major source for mitochondrial fatty acid oxidation (92, 205) . Such regulation would place TAG lipases at the forefront of therapies to modulate fatty acid metabolism in muscle.
The glycerolipid/free fatty acid cycle is not a perfect cycle of complete breakdown and resynthesis of TAG (135), and the lipid intermediates of lipolysis and esterification can generate signaling intermediates, including phosphatidic acid, lysophosphatidic acid, and DAG (described in Other Lipids Act as Signaling Molecules in Skeletal Muscle). The lipid droplet is localized to the endoplasmic reticulum and the mitochondria (71, 159, 166) , which are areas of high lipid flux in the muscle, again providing evidence that the lipid droplet is an important site to appropriately balance fatty acid flux between oxidation and storage. There are major limitations to our current understanding of this cycle. First, appropriate analytical tools are required to quantitatively track fatty acids through cellular compartments; an emerging approach that may address this is correlative light electron microscopy, which combines highresolution electron microscopy with live cell imaging (164) . This may overcome many of the assumptions implemented with "pulse chase" radiotracer experiments. The second limitation is elucidating the subcellular localization of lipolytic and storage enzymes and their possible interactions in muscle. For example, diacylglycerol acyltransferase 2 (DGAT2) was once considered an endoplasmic reticulum enzyme; however, recent studies report the localization of DGAT2 and its substrate (DAG) to the lipid droplet of mammalian cells (102, 113) , where it interacts with the lipid droplet-associated protein PLIN2 (167) . Moreover, DGAT2 is also found on mitochondria (167) , where it may promote the synthesis of TAG into closely associated lipid droplets from excess fatty acyl-CoA. The relevance of these observations to skeletal muscle requires investigation.
The Role of Lipid Droplet Proteins and Fatty Acid Flux in Skeletal Muscle Function
PAT proteins in skeletal muscle. The identification of PLIN1 (50, 66) as a lipid droplet-associated phosphoprotein has led to an explosion of research examining the role of lipid droplet proteins in cell function. PLIN1 is expressed exclusively in mature adipocytes and steroidogenic cells (66, 158) and is the most well-characterized member of the PAT (perilipin, ADRP, TIP-47) protein family, which includes PLIN2 (ADRP, ADFP, and adipophilin), PLIN3 (TIP47, PP17, and M6PRBP1), PLIN4 (S3-12), and PLIN5 (LSDP5, OXPAT, and MLDP). Given the critical role of PLIN1 in adipocyte metabolism, it is likely that other PLIN family members exert important metabolic roles in muscle.
PLIN2. Studies in other cell types indicate that PLIN2 acts largely as a scaffold protein on lipid droplets, and its expression is reciprocally related to tissue TAG content, perhaps by controlling access of ATGL to the lipid droplet (106, 182) . PLIN2 protein content is closely associated with TAG levels in skeletal muscle of endurance-trained cyclists (119, 160) and Zucker diabetic fatty rats (119) , and PLIN2 is dose-dependently increased by fatty acids and pharmacological activation of peroxisome proliferator-activated receptor (PPAR)␣, -␤/␦, or -␥ (40, 41). The relationship between PLIN2 protein and TAG content is complex; approximately two-thirds of PLIN2 localizes with lipid droplets (suggesting that 1 ⁄3 resides elsewhere), and only 60% of all lipid droplets actually contain PLIN2 (134, 160) , suggesting heterogeneity of the lipid droplet pool with subsets of lipid droplets exerting distinct functions. A functional role for PLIN2 has not been demonstrated in skeletal muscle. HSL translocates and colocalizes with PLIN2 during contraction or epinephrine stimulation in isolated skeletal muscle (134) ; however, a direct interaction between HSL and PLIN2 is yet to be demonstrated.
PLIN3/PLIN4. PLIN3 is expressed in skeletal muscle, with some colocalizing with lipid droplets and others forming small cytosolic clusters. The cellular localization of PLIN3 is not altered with contraction or epinephrine administration (134) . PLIN3 is postulated to be involved in lipid droplet synthesis (29), although a functional role is not described for muscle. PLIN4 is the least-described member of the PAT family and is also thought to be involved in the early phases of lipid droplet synthesis under the control of PPAR␥ (40, 195) . PLIN4 is expressed in skeletal muscle, but its function is not described (40).
PLIN5. Studies in 3T3-L1, Chinese hamster ovary (CHO), COS-7, H4IIe, and human embryonic kidney-293T cells show that PLIN5 binds both CGI-58 and ATGL (but not both at the same time) to negatively regulate basal and PKA-activated lipolysis (64, 65, 185) . PLIN5 also interacts with HSL in CHO cells, but this is not enhanced by PKA activation (186) . Thus, PLIN5 appears to be an important regulatory scaffold protein for lipolysis in nonadipocyte cells. PLIN5 is also localized to heart and liver mitochondria, where it appears that overexpression of PLIN5 partitions exogenous fatty acids away from oxidation and into storage as TAG (185) . This is at odds with another study that demonstrated that overexpression of PLIN5 in COS-7 cells increased fatty acid oxidation (194) . PLIN5 is highly expressed in skeletal muscle (oxidative Ͼ glycolytic) (39, 194) , its protein content is closely associated with intracellular TAG levels (119), and its expression increased with PPAR␥ activation (194) . In view of PLIN5's functions described for other cell types and its high expression in muscle, it is possible that PLIN5 may play the role of "master lipolytic regulator" in muscle, much like the role of PLIN1 in adipocytes (120) . Ongoing research should address these issues in the near future.
The lipid droplet proteome in skeletal muscle. The lipid droplet proteome of murine skeletal muscle was described recently to contain 324 proteins (203) , which is comparable with the 293 proteins detected in murine white adipose tissue lipid droplets (94) . Aside from the expected lipid metabolism proteins, the mass spectrometery screen identified a detailed network of proteins, including members of the Rab family, heat shock proteins, and other proteins located in the endoplasmic reticulum and mitochondria. The shared expression supports the histological analysis demonstrating the direct interaction between organelles, but this should be interpreted with caution due to potential contamination from the lipid droplet isolation procedure. Interestingly, apolipoprotein A-I, the principal apolipoprotein of HDL particles, was localized to skeletal muscle lipid droplets, highlighting the likelihood of identifying unexpected roles for known proteins in fatty acid signaling from the lipid droplet.
Lipid droplets and metabolism: does size matter? Although increases in skeletal muscle TAG content are associated with insulin resistance (see Lipid Signals Leading to Insulin Resistance), an apparent anomaly that has perplexed the field is the so called "athlete's paradox," which describes endurancetrained athletes having increased skeletal muscle TAG despite being highly insulin sensitive (63) . The training-induced mitochondrial biogenesis and the accompanying increase in oxidative disposal of fatty acids, subsequent reduction of lipid metabolite levels, and removal of inhibitory signals on insulin signaling are likely and have been addressed extensively elsewhere (46, 172) . Other theories pertaining to lipid droplet morphology and biology have been postulated to explain the athlete's paradox. One possibility is that regular endurance exercise alters the physical properties of lipid droplets, often described as "remodeling." Early reports described smaller lipid droplets in highly trained athletes and following weight loss in obese humans (74); however, the weight of evidence demonstrates no change in lipid droplet size with energy restriction or exercise training (6, 42, 95, 109, 181 ). An alternative theory is that the spatial distribution of lipid droplets may differ between high and low insulin sensitivity; again, this is not supported by robust evidence (110, 181) . Another possibility is that the interaction between the lipid droplet and mitochondria is increased, thereby promoting oxidation of lipolysis-generated fatty acids rather than incorporation of these fatty acids into lipid intermediates that interfere with insulin signaling. Enhanced lipid droplet mitochondrial touching has been observed following exercise training in women (42) and aging (37), but not in the context of the athlete's paradox. Finally, endurance training may alter the protein architecture of the lipid droplet, which may tighten fatty acid flux into and out of the lipid droplet and thereby prevent the accumulation of other lipid metabolites. These possibilities require testing to inform on the factors mediating this athlete's paradox.
Other Lipids Act as Signaling Molecules in Skeletal Muscle
Lipid types other than free fatty acids act as signaling molecules in skeletal muscle. Many of these studies have been performed by adding individual lipids to the incubating medium of cultured cells, thereby representing the effect of (extracellular) plasma-derived lipids on cellular processes. Notably, the same lipids may not exert the same effects if generated within the cell. We have avoided discussion of membrane structure and fluidity, which can regulate a plethora of cellular processes (for review, see Refs. 16, 84, and 165) but have instead focused on lipids acting as ligands or signaling intermediates.
Sphingolipids. A number of sphingolipid species, including sphingosine, sphingosine-1-phosphate (S1P), ceramide, and ceramide-1-phosphate (C1P), accumulate in skeletal muscle or signal via receptors to act as signaling intermediates (28, 58, 126) .
Sphingosine/S1P. S1P is generated from sphingosine by sphingosine kinase (Fig. 1) and is increased in cultured myotubes with palmitate exposure (81) and in skeletal muscle after treadmill running (22). Aside from intracellular generation, S1P also circulates in the plasma, which is associated predominantly with HDL, but is also attached to albumin after secre-tion from platelets, erythrocytes, and endothelial cells (141) . It has been suggested that S1P can act in an autocrine/paracrine manner to activate its receptors and downstream signaling events associated with activation of these sarcolemmal G protein-coupled receptors [S1P 1 , S1P 2 , and S1P 3 (18, 116) ]. S1P can alter calcium handling via transient receptor potential canonical channels (55) that induce muscle contraction (54), activate ERK1/2 and p38 MAPK, calpain/PKC␣, and PKC-␣/ RhoA pathways to stimulate satellite cell differentiation (45, 115, 117, 123) , and transactivate the insulin receptor via redox processes arising from S1P 2 activation to increase glucose uptake (137, 201) . Exercise increases plasma S1P (13) , and based on the above observations, S1P has been proposed to be a lipid-signaling mediator of skeletal muscle repair/differentiation and nutrient utilization during/after exercise. However, a number of these processes may be ascribed to either extracellular activation of the S1P receptors or direct interaction of S1P with intracellular targets (for review, see Ref. 58 ).
Sphingosine is the precursor of S1P and opposes many of S1P's actions. For example, sphingosine binds directly to ryanodine receptors to block calcium release (145) , and sphingosine inhibits PKC activity in vitro (70) . Similar to S1P, intramyocellular sphingosine levels are increased with exercise, and given its effects on calcium homeostasis it has been proposed that sphingosine plays a role in the onset of exerciseinduced fatigue (44) . Thus, the sphingosine/S1P ratio may be an important biological rheostat for several cellular processes, as is the case for other cell types, thereby placing sphingosine kinase as a potentially important regulator of this sphingosine/ S1P balance (133) .
Ceramide/C1P. Generated from ceramide by ceramide kinase in the golgi complex (Fig. 1) , C1P is involved in cell growth, antiapoptotic pathways, and inflammation in several cell types and appears to act via the recently identified C1P receptor (for review, see Refs. 11 and 61). A general finding from other cell types is that C1P has opposing biological , and the fatty acyl-CoA (FA-CoA) can enter the glycerolipid synthesis pathway for storage or the mitochondria for oxidation. Phospholipids can be converted to a number of other lipid types by phospholipid lipases. S1P and lysophosphatidic acid (LPA) synthesis occurs at the sarcoplasmic reticulum. LPA is also generated at the plasma membrane. S1P and LPA stimulate calcium release to stimulate contraction, and LPA also stimulates cell differentiation. Enzymes of metabolic pathways are grouped as colors: blue, lipolysis; brown, glycerolipid synthesis/esterification; green, phospholipid; orange, sphingolipid; purple, glycerolipid breakdown; red, PAT proteins; yellow, organelle labels. Question mark next to arrow highlights this process as being unknown. ACS, acyl-CoA synthase; AGPAT, acyl-CoA:acylglycerol-3-phosphate acyltransferase; ATGL, adipose triglyceride lipase; C1P-R, ceramide-1-phosphate receptor; CerK, ceramide kinase; CGI-58, coactivator comparative gene identification-58; DAG, diacylglycerol; DAGK, diacylglycerol kinase; DGAT, diacylglycerol acyltransferase; ERK1/2, extracellular signal-regulated kinase 1/2; G, glycerol; GPAT, glycerol-3-phosphate acyltransferase; HSL, hormone-sensitive lipase; LPA-R, lysophosphatidic acid receptors; LPLD, lysophospholipid lipase D; MAG, monoacylglycerol; MAGL, monoacylglycerol lipase; mTOR, mammalian target of rapamycin; PA, phosphatidic acid; PAP, phosphatidic acid phosphohydrolase; PAPLA, phosphatidic acid phospholipase; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI3K, phosphatidylinositol 3 kinase; PIP, phosphatidylinositol phosphate; PKC, protein kinase C; PLC, phospholipase C; PLD, phospholipase D; PPAR, peroxisome proliferator-activated receptor; PS, phosphatidylserine; S1P-R, sphingosine-1-phosphate receptor; Sph, sphingosine; PLIN2 and -5, perilipin 2 and 5; SK, sphingosine kinase; LPE, lysophosphatidylethanolamine; LPC, lysophosphatidylcholine.
actions to that of its precursor, ceramide, which is analogous to the relationship between S1P and sphingosine. The understanding of C1P function in muscle is scarce; incubating myotubes in medium containing C1P activates the phosphatidylinositol 3-kinase/Akt, ERK1/2, and mammalian target of rapamycin (mTOR) pathways to stimulated proliferation (60) . The role of ceramide is discussed below.
DAG. DAG activates PKC in vitro (PKC isoform not reported), with DAG species that contain unsaturated fatty acids in the sn-2 position being the most potent, and only in the presence of phospholipid (98) . DAG species containing saturated fatty acids, e.g., dipalmitin (C16:0) and distearin (C18:0), have 25 and 15% of the activity of diolein (C18:1). The most prominent DAG species (Ͼ80%) in skeletal muscle is C16:0/ C18:1 (33), and elucidating the relevance of species-specific effects of DAG on PKC activation is still required. Although there is associative evidence linking an increase in intracellular DAG to PKC activation (for review, see Ref. 176 ), causative evidence for DAG signaling in skeletal muscle in vivo is lacking and probably reflects the difficulty in modulating DAG (species) levels and DAG localization. Moreover, any maneuver designed to alter DAG levels is challenging given the multiple pathways of DAG production/degradation that include, but are not limited to, shuttling of fatty acids through the glycerolipid synthesis pathway [i.e., via glycerol-3-phosphate acyltransferase (GPAT)], DAG production from the degradation of TAG [i.e., via ATGL (12)], and degradation of phosphatidic acid [i.e., in skeletal muscle, lipin-1, which possesses phosphatidate phosphatase enzyme activity (38)] (Fig. 1) .
Phosphatidic acid. Phosphatidic acid (PA) participates in a variety of signaling pathways. Similar to DAG, PA is produced from several sources, including the cleavage of phosphatidylcholine by phopholipase D, the phosphorylation of DAG by DAG kinase, and the acylation of lysophosphatidic acid by lysophosphatidic acyltransferases such as acyl-CoA:acylglycerol-3-phosphate acyltransferases (Fig. 1) . PA is a major regulator of mammalian target of rapamycin (mTOR), where it binds to stabilize the mTOR complex and facilitate its signaling during muscle contraction (51, 79, 127, 183) . Downstream events of mTOR activation include regulation of insulin signaling both negatively (mTORC1) and positively (mTORC2; for review, see Ref. 139 ). Whether PA is requisite for mTOR signaling in skeletal muscle in situations other than muscle contraction, such as fasting/insulin stimulation, is not described in detail.
Lysophosphatidic acid. Lysophosphatidic acid (LPA) is generated via a number of pathways, including the glycerolipid synthesis pathway by GPAT, hydrolysis of PA by LPA-phospholipid lipase 1 and 2, and through the actions of lysophospholipid lipase D on lysophospholipids, including lysophosphatidic-ethanolamine, -serine, and -choline (Fig. 1) . LPA can be secreted by a number of cell types, including adipocytes, platelets, and fibroblasts, to circulate in plasma bound to albumin, where it signals through its G protein-coupled receptors LPA1-5, GPR87, and P2Y5 (for review, see Ref. 10) . Incubation of C 2 C 12 myotubes with LPA activates both ERK1/2 and Akt mitogenic signaling pathways and regulates calcium handling via PI3K and phospholipase C to stimulate contraction (86, 129, 150, 196) . LPA also activates the stressassociated MAP kinases JNK and p38 to induce apoptosis when its activation of the mitogenic pathways is inhibited (86) .
LPA stimulates glucose uptake via activation of LPA1 and -3 signaling through PI3K/Akt and has a synergistic effect on insulin-stimulated glucose uptake in L6 GLUT4myc myotubes (201) . Similar to S1P, there is a need to separate the extracellular-and intracellular-derived LPA signaling; however, evidence from the liver suggests that this will be a difficult task given the presence of both plasma membrane and a nuclear LPA receptor (62) .
Lipid Signals Leading to Insulin Resistance
Lipid accumulation and insulin resistance. Insulin resistance is a major contributor to the development of type 2 diabetes and is broadly described as a reduced sensitivity to insulin by the body's insulin-dependent processes. Skeletal muscle is the major site for insulin-mediated glucose disposal, accounting for ϳ75% of whole body glucose clearance (14) . It has been only 15 years since the publication of the first papers describing a negative relationship between muscle TAG content and insulin sensitivity independent of adiposity (101, 128, 131) . These studies inspired a new wave of research examining the role of lipids in skeletal muscle insulin action. Common experimental models used to examine myocellular lipid-metabolic interactions include, but are not limited to, adding fatty acids to cell culture medium, high-fat feeding in humans and other species, infusing Intralipid and heparin emulsions to increase fatty acid supply (140) , pharmacological blockade of adipocyte lipolysis to decrease fatty acid availability (180) , and genetic knockout/overexpression of proteins to modulate lipid flux (80) . Although intramyocellular TAG has been shown repeatedly to be increased in insulin-resistant states, the general consensus is that TAG is unlikely to directly cause insulin resistance because it is stored within discrete lipid droplets and is thereby unlikely to impact directly on insulin signaling (see above).
Glycerolipids. Intermediates of the glycerolipid synthesis pathway are implicated in the pathogenesis of insulin resistance. The evidence linking DAG and insulin resistance is compelling but not indisputable; DAG accumulates in myotubes rendered insulin resistant by long-chain saturated fatty acids (122) and is elevated in the muscle of obese insulinresistant rodents (177, 188) and humans (85) , the acute elevation of plasma free fatty acids is temporally associated with muscle DAG accumulation and insulin resistance (202) , and inhibiting DGK␦ reduces DAG content and improves insulin action in mice (34). Mechanistically, DAG is thought to activate novel PKC isoforms, and possibly IKK␤ (30, 96), to in turn induce serine/threonine phosphorylation of insulin receptor substrate-1 (IRS-1) and impair downstream insulin signaling (Fig. 2) This scheme is well subscribed to but remains equivocal (36, 144, 157) . For example, endurance-trained, insulin-sensitive athletes have muscle DAG levels similar to type 2 diabetes patients (6) . A major hurdle is that few experimental approaches, if any, have selectively manipulated intracellular DAG levels, independently of other lipid types known to cause insulin resistance, to show conclusively that DAGs are in fact a critical regulator of fatty acid-induced insulin resistance. Moreover, specific DAG species are postulated to have higher activities against PKC isoforms in vitro, and future studies should consider measuring DAG species, rather the DAG content per se, to at least determine whether specific DAGs correlate with insulin resistance. Finally, subcellular localization and compartmentalization of DAG may be altered under different conditions, potentially altering PKC activation and the amplitude of the PKC response.
Other members of glycerolipid pathway are less studied but may induce changes in insulin action. Studies that have added LPA to cultured myotubes claim an insulin-sensitizing effect of this lipid (201) ; however, it is unlikely that LPA generated within muscle is a major contributor to skeletal muscle insulin resistance because flux through this pathway is normally extremely rapid. Studies in mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 null mice, which would be expected to have reduced LPA, demonstrate no effect on skeletal muscle insulin sensitivity (124) . Notably, LPA was reduced in the livers of these mice with concomitant enhancement of hepatic insulin action. Finally, Cazzoli et al. (32) used several novel cell-based approaches to demonstrate a role for PA (specifically dilinoleoyl-PtdH) in the generation of unsaturated fatty acid insulin resistance.
Sphingolipids. The sphingolipid ceramide is considered a key mediator of insulin resistance in skeletal muscle. Ceramide is elevated in insulin-resistant humans (3, 168) , obese insulin-resistant rodents (76, 188, 190) , and muscle cells rendered insulin resistant by palmitate exposure (153) . Furthermore, pharmacological inhibition of de novo ceramide synthesis enhances insulin action in insulin-resistant rodents (76, 179, 198) . Ceramide induces insulin resistance by inhibiting insulin signal transduction principally at Akt/PKB (169) and possibly via activation of the serine/threonine kinase c-Jun terminal amino kinase (151) , which in turn inactivates insulin receptor substrate proteins (77) . One report indicates that ceramide blocks actin remodeling by preventing activation of Rac, which attenuates GLUT4 translocation and glucose uptake independent of ceramide effects on insulin signal transduction (Fig. 2) (87) .
Although the weight of evidence supports an insulin-desensitizing role for ceramide, there is some skepticism in the field owing to the quantitatively small changes in ceramide content (ϳ30 -50%) commonly observed in insulin-resistant conditions (for review, see Ref. 77 ). However, the localization of ceramide is likely to be an important determinant of cell function, and studies in other cell types have been informative. In adipocytes, ceramide localized within caveolin-enriched membranes of the plasma membrane recruits PKC, which in turn promotes association with and repression of Akt activity (23). In this regard, the skeletal muscle membrane/cytosol ceramide ratio is increased in insulin-resistant mice (27), suggesting that such a mechanism may exist in muscle. Further studies examining ceramide localization within skeletal muscle under various insulin-resistant states are required. Finally, an intriguing new concept suggests that activation of the innate immune signaling pathway triggered by Toll-like receptor 4 (TLR4) is required for saturated fatty acid-induced ceramide biosynthesis and insulin resistance in muscle (75) .
It is also possible that plasma-derived ceramides negatively regulate insulin signaling in muscle. There are several reports of a negative correlation between plasma ceramide and insulin sensitivity (73, 76, 82, 149) , and some evidence suggests that ceramides may signal via the TLR4 to desensitize muscle to insulin. Lipopolysaccharide is the classical ligand for TLR4, and recent studies suggest that the saturated fatty acid palmitate, which shares structural similarities to the lipid A-activating component of LPS, contributes to TLR4 activation and the pathogenesis of skeletal muscle insulin resistance (138) . Endogenous ceramide contains a fatty acid moiety (C16 -C24) that resembles the fatty acids within lipid A, and ceramide that is yet to be demonstrated. Enzymes of metabolic pathways are grouped as colors: blue, lipolysis; brown, glycerolipid synthesis/esterification; green, insulin signaling; orange, sphingolipid; red, PAT proteins; yellow, organelle labels. 3-KDS, 3-ketodihydrosphingosine; AS160, Akt substrate of 160 kDa; DGAT, GCV, glucose transporter 4 (GLUT4) containing vesicles; GlcCer, glucosylceramide; GlcCer Synth, glucosylceramide synthase; IKK␤, inhibitor of nuclear factor-B kinase subunit ␤; IRS-1, insulin receptor substrate 1; JNK, c-Jun NH2-terminal kinase; LPAPL, lysophosphatidic acid phospholipid lipase; MLK3, mixed lineage kinase 3; mTORC2, mammalian target of rapamycin complex 2; P, phosphorylation; p85/p110, phosphatidylinositol 3-kinase subunits p85 (regulatory) and p110 (catalytic); PA, phosphatidic acid; palm-CoA, palmitoyl-CoA; PDK-1, phosphoinositide-dependent kinase-1; PP2A, protein phosphatase 2A; ROS, reactive oxygen species; SMS, sphingomyelin synthase; SPT, serine palmitoyltransferase; TLR4, Toll-like receptor 4. shares other structural similarities with LPS (90) . Further supporting this hypothesis is the finding that short-chain ceramides are putative ligands for the TLR4 (53) .
The production of glycosphingolipids, including gangliosides and glucosylceramide, has been implicated in the development of insulin resistance (Fig. 2) . Pharmacological inhibition of glucosylceramide synthase (4) reduces skeletal muscle glucosylceramide content without changes in other lipids known to cause insulin resistance, concurrent with enhanced insulin sensitivity. From a clinical viewpoint, Gaucher disease is characterized by defective catabolism of glucosylceramide and insulin resistance (56) . Gangliosides modulate the activity of several receptor tyrosine kinases, including the insulin receptor, and studies using a small molecule inhibitor of glycosphingolipid synthesis (204) or genetic GM3 synthase deletion (197) ascribe a role for glycosphingolipid accumulation in the development of insulin resistance. Whether these effects were due to direct muscle or secondary effects was not ascertained. We are unaware of studies examining the direct effects of other sphingolipids such as lactosylceramide on muscle insulin action.
A major issue confronting the field is the inability to selectively modulate a single lipid type to confirm causality. Fatty acids are used to form a multitude of lipid types in muscle, and blocking the actions of one biosynthetic/degradation pathway appears to redirect the fatty acids to an alternative fate. For example, reducing palmitate-induced ceramide accumulation by serine palmitoyltransferase short hairpin RNA or pharmacological serine palmitoyltransferase suppression induces a partitioning of palmitate toward DAG in myotubes (187) or TAG in rodent muscle (179) . Hence, when modifying a protein/pathway of lipid metabolism, consideration of the global changes in the muscle lipidome and the effects on downstream metabolic processes is required.
Do byproducts of fatty acid oxidation cause insulin resistance? Researchers have spent considerable effort attempting to explain how lipid excess causes insulin resistance. Until recently, many subscribed to the theory that reducing fatty acid storage in muscle cells, by decreasing their uptake or increasing their oxidation, would alleviate the intracellular "lipid stress" imposed by "bioactive lipid metabolites" and improve muscle insulin action (see above). Indeed, experimental maneuvers that have increased fatty acid oxidation selectively in skeletal muscle demonstrate a diminution of insulin resistance in the setting of fatty acid overload (19, 27, 35, 99, 130) . Notably, this is not always associated with decreases in muscle lipid content, implying that increasing the mitochondrial flux of incoming fatty acids is somehow protective for muscle cells. This conclusion is supported somewhat by acute exercise/contraction studies that demonstrate (infer) increased lipid catabolism, mitochondrial fatty acid flux, and protection against lipid-induced insulin resistance (152, 174, 175) . Koves et al. (100) presented an alternative and provocative concept, suggesting that the metabolic link between lipid oversupply and insulin resistance in skeletal muscle is explained by a disconnect between excessive mitochondrial ␤-oxidation and flux through the TCA cycle. The investigators used several experimental models to support the notion that a rise in ␤-oxidation with an accompanying production and accumulation of acylcarnitine and a concurrent reduction in TCA cycle intermediates reflect a state of mitochondrial stress, which in turn causes insulin resistance. Thus, according to this theory, defective insulin action in skeletal muscle is tightly coupled to dysregulated mitochondrial bioenergetics when fatty acid is the principle substrate. This concept is supported by studies demonstrating increased "incomplete" fatty acid oxidation in primary myotubes obtained from severely obese vs. lean (17) or type 2 diabetes vs. obese human subjects (193) , with concomitant reductions of insulin signal transduction (17) . The obesity phenotype was recapitulated in muscle cells from lean subjects exposed to excess fatty acids. However, there was no evidence of insulin resistance in a model of iron deficiency where ETC capacity is reduced and uncoupled from TCA cycle flux (69) .
A major unanswered question pertaining to this hypothesis is what are the signaling events mediating insulin resistance with excessive ␤-oxidation? Acetylcarnitine accumulates in skeletal muscle with high-fat feeding in humans (136) , but whether specific acetylcarnitines act as signaling molecules or indirectly modify protein acetylation is unknown. Alternatively, excessive flux through ␤-oxidation could provide excess acetyl-CoA for acetyltransferase activity on key proteins regulating insulin action. However, acetylation of IRS-1 appears to enhance insulin-stimulated signal transduction (91) , and inhibiting histone deacetylase activity (and thereby facilitating acetylation) appears to promote insulin sensitivity (114, 118) .
Next, the identity of the "incompletely oxidized" metabolites being measured in the cultured preparations remains a mystery, and insight into these molecules may provide the metabolic link to insulin resistance. Seifert et al. (156) have utilized a novel, unbiased metabolomics profiling approach to identify metabolite signatures of palmitate combustion in skeletal muscle mitochondria. It appears from these initial studies that TCA cycle intermediates (citrate, ␣-ketoglutarate, succinate, malate) and ketone body production are possible targets of future investigation. Other likely candidates include reactive oxygen species (ROS), which can activate serine kinases and interfere with insulin signal transduction. Palmitoyl-L-carnitine substrate increases H 2 O 2 emission in isolated mitochondria compared with pyruvate (8), whereas high-fat diets lead to an increased H 2 O 2 -emitting potential of skeletal muscle mitochondria in the absence of any change in respiratory function, resulting in a shift in the intracellular redox environment to a more oxidized state (7). Thus, acutely, fatty acid ␤-oxidation generates more ROS, and prolonged fatty acid exposure leads to stable changes that promote ROS production irrespective of the mitochondrial substrate. Just how prolonged exposure to fatty acids alters the H 2 O 2 -emitting potential of mitochondria in skeletal muscle is unclear, but presumably this must involve a change in the control of electron leak from the electron transport system or the rate of H 2 O 2 scavenging in the mitochondrial matrix. Of note, ROS formation during mitochondrial fatty acid oxidation occurs at very low concentrations in vitro (4.5 M palmitoylcarnitine) and involves a complex process involving multiple sites of ROS production, with complex III (not complex I) and the less appreciated membrane potential-independent electron transfer flavoprotein and electron transfer flavoprotein oxidoreductase as likely sites of ROS production (155) . (Readers are directed to a review by Dr. Scott Powers in a future issue of this journal for further information on this topic).
Another unresolved question is why do mitochondrial fatty acid transport and catabolism exceed TCA flux when, typically, signals generated from the TCA cycle provide feedback to tightly modulate the activities of several enzymes involved in fatty acid catabolism (e.g., CPT I, ␤-ketothiolase)? Is there really a dysregulation of this feedback system, or does this insensitivity reflect the inadequacies of performing experiments in isolated mitochondria and/or immortalized cells in vitro, where substrate is always supplied in excess of requirements and upstream regulation of fatty acid metabolism is removed or compromised.
Conclusions
It is clear that lipids and their metabolites induce innumerable regulatory processes within skeletal muscle and that dysregulated lipid metabolism is related to several pathological disorders, most prominently insulin resistance. Studies in other cell types have provided a road map to understanding lipidsignaling processes, and although there has been a growing interest and progression in this broad field, owing notably to the progress in lipid mass spectrometry and lipid imaging, there is still much to learn about lipids and their role in regulating muscle in health and disease. Such pressing questions include the following: 1) What is the actual function(s) of some of the key proteins in regulating lipid levels in muscle, e.g., FAT/CD36, PLIN5, AMPK? 2) What processes regulate lipid droplet number and size, what proteins coat the muscle lipid droplet, and do changes in the size of the lipid droplet alter function? 3) What proportion of extracellular-derived fatty acids enters the lipid droplet, does movement through the lipid droplet provide a central point of lipid control, and how can we accurately (quantitatively) track fatty acids to their end point and beyond (tracer methodology, immunofluorescence/ mass spectrometry imaging)? 4) How does the cellular localization of lipids impact on function, and is it sufficient to use whole cell homogenates? 5) Do specific lipid species impart differential effects on cell function, and how can we experimentally tease out species-dependent effects in cell systems/ tissues? 6) Are there noteworthy muscle fiber type effects in enzyme capacities of other lipid synthesis/degradation pathways that result in divergent signaling between oxidative/ glycolytic muscle? And 7) which lipid signals are primarily responsible for the induction of insulin resistance in obesity and upon high-fat delivery/diet? 
